Skip to content
Recall Observatory FDA recall evidence

Drug product

MethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/5 mL (80 mg/mL), 5 mL Multiple-Dose Vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0703-0063-01.

D-0284-2021

February 10, 2021

Class II

Product summary

Firm
Teva Pharmaceuticals USA
Event
Event 87298
Status
Terminated
Classification
Class II
Quantity
15,043 vials
Official record key
drug-enforcement:D-0284-2021

Official wording

Reason: Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Code information: Lot # 31327738B, exp. date 03/2021

Distribution pattern: Product was distributed nationwide in the USA and Puerto Rico.

Derived failure modes

  • Sterility assurance

    reason.sterility_assurance · v1.0.0

    Lack of Assurance of Sterility